Previous experiments using this K7M2 metastatic osteosarcoma model have shown that low-dose anti-CTLA-4 can synergize in combination with anti-PD-L1 therapy to confer some level of durable tumor-free survival, but it is completely ineffective as a monotherapy in this model.19 The gene discussed is CTLA4; the disease is neoplasm.